All posts by imreal

Ingredients for Living Well as Long as Possible, Upcoming Webinar Hosted by Xtalks


Find out how to apply the recent research with specialized carotenoids, Aquamin® and NADH to support wellness, reduced frailty maintaining mental and physical youthfulness.

In this webinar, participants will learn about top ingredients to consider for healthy aging formulas. Attendees will hear about recent science regarding brain function, cellular health, visual processing and nootropic applications. Find out how to apply the recent research with specialized carotenoids, Aquamin® and NADH to support wellness, reduced frailty maintaining mental and physical youthfulness. In addition, learn about boosting cellular health and energy towards cognition, memory, energy and mood-support.

Register for this webinar today and learn more about the top ingredients and current research on super aging.

Join Professor John Nolan, PhD, Fulbright Scholar and Chair for Human Nutrition Research at the School of Health Science, Waterford Institute of Technology, Ireland; David O’Leary, Food Division Manager, Marigot; and Jim Roufs, MS, RD, Owner of Intelligent Nutrition & Scientific Advisory Board Member, for the live webinar on Thursday, February 23, 2023, at 1pm EST (10am PST).

For more information, or to register for this event, visit Super Aging: Ingredients for Living Well as Long as Possible.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Idaho Talent Fest puts out open call for performers to take part in this annual benefit event for FSHD Muscular Dystrophy


Idaho Talent Fest issues open call for auditions!

Volunteer leaders of the Idaho Chapter of the FSHD Society spearheaded a creative way to engage Idaho residents in their goal to fund crucial research to treat fascioscapulohumeral muscular dystrophy (FSHD). Auditions will be accepted via online submission, through March 1st at IdahoTalentFest.org.

In 2021, volunteer leaders of the Idaho Chapter of the FSHD Society spearheaded a creative way to engage Idaho residents in their goal to fund crucial research to treat fascioscapulohumeral muscular dystrophy (FSH muscular dystrophy or FSHD), a rare disease that directly impacts their family when they launched the Idaho Talent Fest.

This 3rd annual talent competition is open to all interested performers. Auditions will be accepted via online submission, through March 1st at IdahoTalentFest.org. After the submission deadline, auditions will be screened, and the contestants will be presented online for the public to vote to determine the finalists. Online voting will be open March 3 through 17, with the final slate of finalists announced on March 20th, 2023. (Contestants must be 12 years of age or older to participate.)

The live event will spotlight and celebrate many talented area residents while raising funds and awareness for those suffering from FSH Muscular Dystrophy. Finalists will perform in front of judges and a live audience on Saturday, April 29th at the Boise State University Special Events Center. Awards of $1,000, $500, and $250 will be given to our first, second, and third place winners, respectively. In addition, there will be first, second, and third place People’s Choice Awards determined by votes from the audience (live and via livestream).

The Idaho Chapter of the FSHD Society is run entirely by dedicated volunteers. Many community businesses are supporting the effort and making it possible; the event is being presented by Aesthetic Eye, PC, the evening will be hosted by radio duo, Rick and Carly from 96.1 Bob FM, and it will be streamed online by Argos Productions.

The FSHD Society is the world’s largest research-focused patient organization for facioscapulohumeral muscular dystrophy (FSHD), one of the most prevalent forms of muscular dystrophy. Over the past 30+ years, the organization has catalyzed major advancements and worked to accelerate the development of treatments and a cure to end the pain, disability, and suffering endured by one million people worldwide who live with FSHD. “As long as we are here, no patient need ever face this disease alone.”

###

For more information about this event, the audition process, or FSHD, please contact Minette Hale at 208.608.2418 or IdahoChapter@FSHDSociety.org

Share article on social media or email:

Gracie Gym Brazilian Jiu-Jitsu Opens Academy in Windham, Maine


Gracie Gym, founded by Crolin Gracie in Brazil, operates several locations worldwide.

The academy in Maine is owned by Michael Smith, a native of Portland, Maine where he grew up on Munjoy Hill. Michael started his Jiu-Jitsu journey in late 2015 and became the first white-to-black belt for Gracie Gym in the United States.

Michael opened his own Gracie Gym location in Dallas, Texas in 2017 and he is thrilled to finally bring Gracie Jiu-Jitsu to his own home state of Maine.

Brazilian Jiu-Jitsu really entered the hearts of Americans when they watched Royce Gracie win the first UFC Championship in 1993, where he put on a stunning display of grappling mechanics against larger opponents who were experts in other forms of combat.

Since then, Brazilian Jiu-Jitsu has become the most dominant martial art combat sport in the world.

Gracie Jiu-Jitsu is designed for any individual who wants to learn self-defense, build confidence and have a new experience with exercise unlike any other. Gracie Gym Maine offers classes for adults and children ages 4 and older. Most students start as beginners who have never trained before and all foundational classes are designed to introduce the basic concepts.

In addition, Gracie Gym Maine will be a place for seasoned Jiu-Jitsu practitioners and high-level competitors to continue to refine their game. With a schedule full of classes starting at 6am and throughout the day, Gracie Gym Maine will have classes to accommodate anyone’s schedule.

The facility is over 7000 square feet and has over 3000 square feet of mat space, a weight room, and a recover lounge with infrared sauna and cold plunge. Additionally, there is plenty of seating and 5 changing rooms. For more information or to schedule a free trail class, please visit http://www.GracieGymMaine.com.

Share article on social media or email:

Newest uMotif Product Release Builds on Track Record of Delivering Patient-Centric, Next-Gen eCOA/ePRO for Faster, Higher Quality Clinical Trials, Real-World Studies


News Image

uMotif – one of the clinical trial technology market’s fastest growing companies – continues to accelerate the pace and quality of clinical, real-world and post-marketing research with new enhancements to its feature-rich, eCOA/ePRO platform built with patients for patients to achieve unprecedented levels of engagement and compliance.

Enhanced uMotif platform capabilities include…

Adaptive Scheduling and Questionnaire Engine – provides highly flexible and responsive solutions for fast configuration of complex study designs, which ensures there are no limitations on how and when interactions, visits and data capture from participants can occur. The scheduler supports any trial design, and effortlessly responds to mid-study updates while continuing to maximize patient engagement. Combined with a powerful questionnaire builder, the enhanced uMotif platform can rapidly add validated eCOA instruments and study-specific eDiaries to the sponsor’s uMotif questionnaire library. Swift questionnaire builds significantly speed up study timelines, helping sponsors move faster from protocol to FPI.

Comprehensive Patient Engagement Toolkit – now, more than ever, sponsors and CROs are seeking tools that put patients at the center of the trial, engaging them to remain in the study and compliant with eCOA/ePRO capture. A new suite of engagement tools further solidifies uMotif’s leadership in delivering patient-centric research. Through the highly configurable app, uMotif engages every patient, in every study. The toolkit includes best-in-class onboarding, home screen, content, notifications and reminders powered by uMotif’s proprietary engine and design approach. Available across iOS, Android and the web, patients receive a compelling companion experience for their study, helping drive greater than 90% compliance.

Advanced Analytics and Custom Reporting – offers CROs, sponsors and sites a customizable view of patient-by-patient data unique in the eCOA/ePRO market. Custom reports and advanced engagement analytics eliminate the need for cumbersome Excel spreadsheets, making decision making accurate, quick and easy. For sites, patient-level data provides a deeper understanding of progress through the study. Robust reporting ensures patients are engaged and capturing all required data, and that sites can easily manage recruitment and compliance. Because reports are configurable at a study level, there are no limits on the kind of reporting the platform generates, from the most complex data queries and eligibility reports, to advanced visualizations.

The enhanced platform capabilities are another example of how uMotif continues to transform the eCOA/ePRO market. Recently the company announced its proprietary Motif data capture interface was independently validated as an alternative to text-based instruments for clinical, post-marketing and real-world research. This marks the first innovation in eCOA/ePRO since paper instruments were deployed on smartphones. (Read more here.)

“The latest release of uMotif’s platform continues to demonstrate what next-generation eCOA/ePRO and industry innovation truly mean,” CEO Steve Rosenberg (LinkedIn) said. “It starts with providing patients with easy-to-use apps that are engaging and akin to those they are familiar with in their daily lives, which in turn drives high compliance rates for sites and sponsors.”

About uMotif

The uMotif eCOA/ePRO platform delivers faster, quality clinical trials and real-world studies by putting patients at the core of research. Through cloud-hosting in the US, Europe and China, the GCP, 21 CFR Part 11 and GDPR-compliant platform supports any study or trial, from Clinical Phase I, II and III studies through to any type of decentralized or virtual real-world study. For more information visit http://www.umotif.com

Share article on social media or email:

RapidScreen Named Exclusive Reseller in Canada for Lucira’s PCR-Quality Check-IT and COVID-19 & Flu At-Home Molecular Tests


RapidScreen Logo

RapidScreen Logo

RapidScreen Services Inc is a leading provider of technology services and health screening for the film and television industry, as well as government and high-availability businesses. Today, the company announced that it is the exclusive Canadian reseller for the Lucira Check IT COVID-19 Test, the first over-the-counter, Health Canada-authorized COVID-19 molecular test, as well as the Lucira COVID-19 & Flu combination test. These molecular, PCR-quality tests are packaged and designed for self-testing at home, in the office, or on set, making it easy for individuals to take control of their health and protect themselves and their loved ones. RapidScreen’s clients include some of the most well-known and respected names in the industry, such as Disney, Netflix, Paramount, Canada Post, and AppleTV.

Developed by Lucira Health Inc., the test has been authorized by Health Canada and is now available to institutions, healthcare providers, agencies, and consumers in time for the busy COVID and Flu season. The Lucira COVID-19 & Flu Test is a 99% accurate rapid molecular PCR-quality test that delivers results in 30 minutes or less from one shallow nasal swab.

“We are thrilled to be able to offer these innovative products from Lucira Health to businesses, consumers, and institutions in Canada. The Lucira platform represents a major breakthrough in the fight against infectious diseases and will play a crucial role in keeping communities safe and healthy.” said Dr. Dennis Reich, CEO of RapidScreen, “Immediate, reliable and actionable results on common infectious diseases is the game changer everyone is looking for in healthcare.”

Lucira Health’s single-use test is a compact and convenient solution for quickly and accurately detecting COVID-19, Flu A, and Flu B that fits in the palm of your hand and runs on just two AA batteries. With a simple nasal swab sample, it provides a positive or negative result in 30 minutes or less. Each test comes packaged with everything you need. There is no need to purchase a separate reader or instrument. Simply follow the included instructions to quickly and easily obtain reliable results.

Lucira Health’s testing platform is a highly accurate and reliable solution for detecting infectious diseases. The Nucleic Acid Amplification Test (NAAT) used in the platform has sensitivity and specificity comparable to lab-based PCR assays. In November 2020, the Lucira standalone COVID-19 Test was the first at-home molecular COVID-19 test to receive an Emergency Use Authorization (EUA) from the FDA. More recently, the Lucira COVID-19 & Flu Test, which uses the same technology platform, was granted an EUA for point-of-care use. These EUA’s speak to the effectiveness and reliability of Lucira’s testing platform in detecting COVID-19 and other infectious diseases.

Health Canada has granted authorization under Interim Order No. 3. for the emergency use and commercialization of this first and only at-home test for COVID & Flu. Health Canada’s decision is based on performance data including clinical trial results demonstrating comparable sensitivity and specificity to leading lab-based PCR assays.

The test also recently received CE marking, meeting EU health and safety requirements. Submissions to other regulatory authorities are in progress.Inquiries can be sent to RapidScreen – press@rapidscreen.com

About RapidScreen

RapidScreen Services Inc is a leading provider of rapid testing, tracking, and technology services for the film and television industry, small to medium-sized businesses (SMB), and government organisations. Our team of experienced professionals is dedicated to helping our clients keep their communities safe and healthy by providing the most advanced and reliable solutions on the market. From rapid COVID-19 and flu tests to comprehensive tracking and technology services, we have the expertise and resources to meet the needs of a wide range of clients. We are proud to be the exclusive reseller in Canada for the innovative products offered by Lucira Health, and we look forward to helping our clients take advantage of these game-changing solutions. For more information, visit http://www.rapidscreen.com.

About Lucira Health

Lucira is a medical technology company focused on the development and commercialization of innovative infectious disease tests to make lab-quality diagnostics more accessible. Lucira designed its test platform to provide accurate, reliable, PCR-quality test results anywhere and at any time. Beyond its already commercialised COVID-19 and COVID-19 & Flu Tests, Lucira is working on new diagnostic tests for respiratory infections and other categories including women’s health and sexually transmitted infections (STIs). For more information, visit http://www.lucirahealth.ca.

Share article on social media or email:

Start with Tart this February – National Hot Breakfast Month


Cranberry Roasted Breakfast Bowl

What’s better than beginning a cold winter day with a delicious, hot breakfast? Beginning your day with a delicious, hot breakfast featuring America’s Original Superfruit®, of course!

Starting with tart, also known as cooking breakfast with cranberries, is an easy and delicious way to incorporate unique flavor, color, and nutrients into recipes. Some simple ways to #StartWithTart include:


  • Stir dried cranberries into oatmeal
  • Simmer cranberry concentrate into syrup
  • Incorporate fresh or frozen cranberries into pancake or waffle batter
  • Top toast and bagels with cranberry sauce
  • Add dried, fresh or frozen cranberries to muffin mixes

Cranberries offer big health benefits in a tiny package, including unique polyphenols not commonly found in other fruits. A serving of fresh or frozen cranberries contains fiber (1.8 g), Vitamin C (7 mg), Vitamin A (31.5 IU) and many other nutrients. Cranberry juice is also an excellent source of Vitamins C and E and a good source of Vitamin K. All forms of cranberry are sodium free, fat free and cholesterol free.

When searching for new ways to use cranberries, visit http://www.uscranberries.com/recipes, which contains nearly 500 recipes including the following hot breakfast ideas:

About the Cranberry Marketing Committee

The Cranberry Marketing Committee (CMC) promotes the worldwide use and consumption of US-grown cranberries. The CMC was established as a Federal Marketing Order in 1962 to ensure a stable, orderly supply of good quality product. Follow @USCranberries on Facebook, Twitter and Instagram.

Share article on social media or email:

Joseph Simone Calls New York’s Workforce Development Essential for Life Sciences Real Estate Growth


News Image

“New York is successfully attracting life science startups. The challenge now is to build talent pipelines to train the necessary workforce that will enable the state to achieve its employment goals,” said Joe Simone, President of Simone Development Companies.

New York’s planned investments in life science workforce training centers will help stimulate real estate development, said Joseph Simone of Simone Development Companies.

“New York is successfully attracting life science startups. The challenge now is to build talent pipelines to train the necessary workforce that will enable the state to achieve its employment goals,” said Joseph Simone, President of Simone Development Companies. “State investments in the New York City regional workforce development plan ensure that growing life science companies seeking real estate in the tri-state area will find the right workers to fill new laboratories and facilities.”

The Long Island Investment Fund recently announced its intention to fund a life science workforce development training center. One of the fund’s goals is to supercharge the life sciences ecosystem in the region by developing workers with in-demand skills.

LifeSci NYC has a similar role in the five boroughs, and one target area is in the Bronx at the Montefiore-Einstein Accelerated Biotechnology Research Center (EMBARC), located across the street from Simone Development Companies’ Hutchinson Metro Center. EMBARC is a biomanufacturing operation focused on cell, gene, and antibody production. LifeSci NYC will invest $20 million to build a diverse pipeline of life sciences talent.

Simone Development Companies has anticipated growth in Morris Park’s biotech talent pool by planning for a live-work-play environment at the Hutchinson Metro Center, a mixed-use medical-office complex where future construction may include life science labs, housing, and destination retail catering to the employees of companies that grow out of EMBARC. This emerging innovation hub will be connected to New York City’s life sciences network by Metro-North’s future Morris Park train station, which will provide quick access to Penn Station in Manhattan.

“Since 2018, biotech research and development companies have increased employment by more than 8,000 people in the New York City metro area, an almost 20 percent increase. “Industry leaders say this growth will continue, and our Hutchinson Metro Center is well positioned to meet the increased demand for real estate that can accommodate life science facilities and workers,” said Megan Guy, Simone Development Companies’ Senior Vice President of Development.

Simone Development Companies is a full-service real estate investment company specializing in the acquisition and development of healthcare, mixed-use, office, industrial, retail, and residential properties. Headquartered at the Hutchinson Metro Center, it boasts a portfolio of over 7 million square feet throughout the Bronx, Manhattan, Queens, Long Island, Westchester County, Orange and Fairfield Counties and New Jersey. With services spanning acquisition, development, construction, finance, asset management, accounting, leasing and property management, Simone Development Companies is set apart by its vertically integrated management team, long-term asset ownership and its pursuit of visionary development.

Share article on social media or email:

Raw Sample Genotyping Patents Available on the Ocean Tomo Bid-Ask™ Market


OceanTomoBidAsk.com

The system and method covered within the lot could revolutionize DNA testing bypassing DNA purification of raw samples.

Ocean Tomo announces the auction of Raw Sample Genotyping Patents, available as lot 166, on the Ocean Tomo Bid-Ask™ Market.

The patent auction, lot 166, consists of twelve U.S. and international patents including:

  • Blood typing using DNA
  • Methods for PCR and HLA typing using raw blood
  • Methods for PCR and HLA typing using unpurified samples
  • Use the method for PCR and the HLA Somatotype of crude blood

The patents cover a method of performing tandem PCR amplification to bypass DNA purification. It automatically obtains consistent measurable amounts of DNA without extra cost and labor. The portfolio is applicable to a wide variety of samples including saliva, blood and fecal across analytical platforms.

The system and method covered within the lot could revolutionize DNA testing bypassing DNA purification of raw samples. With this system, raw samples can be directly used for analysis while continuing to provide comparable quality of results as a purified DNA sample. This system is more cost effective and decreases time between sample collection and application.

The portfolio provides an attractive opportunity for hospitals and maternity centers, medical device manufacturers, drug and medication manufacturers, and large-scale labs to revolutionize their sample purification and analysis processes.

To request bidder credentials or to receive further information on this portfolio available on the Ocean Tomo Bid-Ask™ Market, contact Christopher Bruce at christopher.bruce@jsheld.com or +1 312 327 8022.

About Ocean Tomo, a part of J.S. Held.

The Ocean Tomo Bid-Ask™ Market (OTBA) was built to further enhance Intellectual Property (IP) liquidity and transaction transparency. OTBA serves a broad community of active buyers and sellers, providing a platform to purchase or sell patents and patent applications globally. This market is supported by Ocean Tomo Transactions and affiliate international voice brokers.

Established in 2003, Ocean Tomo provides Financial Expert, Management Consulting, and Advisory services related to intellectual property (IP) and other intangible assets; corporate accounting investigations; regulatory and reporting obligations; solvency and restructuring; and contractual or competition disputes. Practice offerings address economic damage calculations and testimony; accounting investigations and financial forensics; technology and intangible asset valuation; strategy and risk management consulting; mergers and acquisitions; debt and equity private placement; and IP brokerage. Subsidiaries of Ocean Tomo include Ocean Tomo Investments Group, LLC, a registered broker-dealer.

As a part of J.S. Held, Ocean Tomo works alongside more than 1500 professionals globally and assists clients – corporations, insurers, law firms, governments, and institutional investors – on complex technical, scientific, and financial matters across all assets and value at risk.

J.S. Held is a global consulting firm providing technical, scientific, and financial expertise across all assets and value at risk. Our professionals serve as trusted advisors to organizations facing high-stakes events demanding urgent attention, staunch integrity, clear-cut analysis, and an understanding of both tangible and intangible assets. The firm provides a comprehensive suite of services, products, and data that enable clients to navigate complex, contentious, and often catastrophic situations.

Share article on social media or email:

APSHO Announces Launch of New Cancer Therapy Prescribing Course


News Image

This course fulfills an unmet need – the need for a universal and comprehensive tool to educate oncology APs in the safe prescribing of cancer therapy

The Advanced Practitioner Society for Hematology and Oncology (APSHO) is proud to announce the launch of the APSHO Cancer Therapy Prescribing Course (CTPC). This comprehensive, online course consists of 19 self-paced, interactive educational modules designed to prepare the advanced practitioner (AP) to safely prescribe and manage cancer therapeutics. The Cancer Therapy Prescribing Course provides peer-reviewed, advanced education in the treatment and management of the hematology/oncology patient through the course of cancer therapy and includes safe prescribing recommendations, treatment access devices, the prevention and management of infusion reactions, patient education, and clinical trial prescribing.

“This course fulfills an unmet need – the need for a universal and comprehensive tool to educate oncology APs in the safe prescribing of cancer therapy,” commented APSHO’s Executive Director Wendy Vogel, MSN, FNP, AOCNP®, FAPO. “We believe that APs should practice at the top of their professional scope; this course, in conjunction with appropriate mentorship by the cancer institution, will enable them to do so.”

Briana Hoffner, MSN, AOCNP®, FAPO, BroadcastMed’s Chief Medical Officer, noted, “APSHO’s Cancer Therapy Prescribing Course was developed by an expert, dedicated, multidisciplinary group of APs, including pharmacists, physician assistants, and nurse practitioners. The course encompasses all of the required educational domains for the safe prescribing of cancer therapy.”

The CTPC will offer 25 credits/hours of CE-certified education for nurse practitioners, pharmacists, physician assistants, and advanced practice nurses. The course will be housed online in APSHO’s new AP Academy, found online at apsho.org/page/apacademy, along with other educational opportunities.Learn more about APSHO at APSHO.org.

About APSHO

The Advanced Practitioner Society for Hematology and Oncology (APSHO) is a society for advanced practitioners: nurse practitioners, physician assistants, pharmacists, clinical nurse specialists, and other oncology health-care professionals. The mission of APSHO is to promote oncology patient care that is high quality, cost effective, and delivered through collaborative practice models by optimizing the role of the advanced practitioner as an integral member of the care team.

Share article on social media or email:

EDPMA Supports Texas Medical Association’s Opposition to a 600% Increase in Administrative Fees For Physicians Utilizing No Surprises Act Independent Dispute Resolution


News Image

The dramatic, unprecedented increase in initial fees disproportionately affects providers, favors health plans, and will hurt patients.

The Emergency Department Practice Management Association (EDPMA) fully supports the Texas Medical Association’s lawsuit holding the Department of Health and Human Services, Department of Labor and the Department of Treasury (the Departments) accountable and demanding they reverse its 600% administrative fee increase for clinicians to participate in the Independent Dispute Resolution (IDR) process as intended by the No Surprises Act.

The Texas Medical Association’s (TMA) fourth lawsuit filed against the federal government asserts that the Department’s unlawful exorbitant administrative fee increase to initiate the IDR process harms physicians and the patients they serve. This 600% increase in the non-refundable fee must be paid by disputing parties to access the Federal IDR process and is a substantial obstacle for physicians’ ability to seek redress for unsubstantiated underpayments from health plans for services provided to insured patients seeking emergency care. The dramatic, unprecedented increase in initial fees disproportionately affects providers, favors health plans, and will hurt patients.

“While EDPMA understands CMS’ need to address the IDR backlog, exorbitant fees are simply not the answer. These abrupt, inappropriate increases unnecessarily burden emergency medicine clinicians and significantly deter clinicians’ access to the method of dispute resolution provided by Congress. This is another substantial misstep that fails to address fundamental operational and policy-related issues involved in the No Surprises Act,” said Don Powell, DO, FACEP, EDPMA Chair.

“CMS’s actions prevent the level playing field provided in the law, and contrary to the law’s interests, will drive more payer-driven contact terminations, while crippling the cash flow that supports emergency care for patients,” says Powell.

EDPMA fully supports the Texas Medical Association and their lawsuit to protect patients, physicians and the healthcare system, and urges the Departments to reinstate the originally announced $50 federal IDR administrative fee.

###

About EDPMA

The Emergency Department Practice Management Association (EDPMA) is the nation’s largest professional physician trade association focused on the delivery of high-quality, cost-effective care in the emergency department. EDPMA’s membership includes emergency medicine physician groups of all sizes, as well as billing, coding, and other professional support organizations that assist healthcare providers in our nation’s emergency departments. Together, EDPMA’s members deliver (or directly support) health care for over half of the 146 million patients that visit U.S. emergency departments each year. Visit http://www.edpma.org.

Share article on social media or email: